Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
GREENFIELD, Ind. - Elanco Animal Health Incorporated (NYSE:ELAN), a profitable animal health company with robust gross margins of nearly 55%, announced today that the U.S. Department of Agriculture has approved its TruCan Ultra CIV H3N2/H3N8 vaccine for canine influenza. According to InvestingPro data, the company has demonstrated strong financial health with liquid assets exceeding short-term obligations.
The newly approved vaccine is designed to provide protection against both H3N2 and H3N8 strains of canine influenza virus in a half-milliliter dose. According to the company’s press release statement, the vaccine demonstrated 100% virus neutralization against 33 current field isolates in studies.
TruCan Ultra CIV completes Elanco’s Tru Portfolio of vaccines, which are made with the company’s PureFil Technology, a process for creating purified vaccines.
Bobby Modi, Executive Vice President of U.S. Pet Health and Global Digital Transformation at Elanco, said the vaccine "offers broad protection against canine influenza" and "integrates seamlessly into our Tru Portfolio."
The company noted that respiratory disease outbreaks can significantly impact veterinary clinics, sometimes leading to facility closures. Certain dog breeds, particularly brachycephalic breeds with flat faces such as French Bulldogs and Pugs, can be at higher risk for severe symptoms associated with respiratory diseases.
In studies, the company reported that no vaccinated dogs developed lung lesions after being challenged with the H3N2 strain, and the vaccine was proven to reduce viral shedding.
Elanco’s vaccine line is recommended by Fear Free, an organization focused on preventing fear and anxiety in pets during veterinary care.
The TruCan Ultra CIV vaccine is now available for pre-order and will ship within the next 30 business days, according to the company. With the stock trading near its 52-week high and showing strong financial metrics, investors can access detailed analysis and additional insights through InvestingPro, which offers comprehensive research reports covering over 1,400 US stocks, including Elanco Animal Health.
In other recent news, Elanco Animal Health has announced several key developments that may interest investors. The company reaffirmed its second-quarter and full-year guidance, underscoring its commitment to strategic objectives during a period of growth and innovation. Elanco’s canine allergic dermatitis treatment, Zenrelia, received a positive opinion from the European Medicines Agency, positioning it for marketing authorization in the European Union. The firm expects to launch Zenrelia in EU markets before the end of the third quarter.
Analysts have also weighed in on Elanco’s prospects. Stifel raised its price target on Elanco to $17, citing parasiticide share gains and improved relationships with veterinarians. William Blair upgraded Elanco’s stock rating to Outperform, highlighting the stabilization of its core business and a promising innovation pipeline. Meanwhile, Leerink Partners increased its price target to $14.50, though it maintained a Market Perform rating due to uncertainties about product uptake. Additionally, Elanco appointed Robert VanHimbergen as the new Chief Financial Officer, effective July 7, 2025, signaling a strategic move to bolster its financial leadership.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.